Cingulate Inc. (CING) Free cash flow
- Free cash flow · 12 months (USD): Value $-20.94M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-20.94M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-20.65M − $284.48K ≈ $-20.94M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-20.65M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.72× | Operating cash flow / net income. Period ending 2026-06-30. $-20.65M ÷ $-28.80M ≈ 0.72× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -20.65M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 284.48K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -20.94M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -28.80M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-20.94M | (m) | $-20.65M | $284.48K | (m) | (m) | (m) | $-28.80M | (m) | (m) | (m) | 0.72× |
| 2026-03-31 | (m) | (m) | $-19.55M | (m) | (m) | (m) | (m) | $-27.91M | (m) | (m) | (m) | 0.70× |
| 2025-12-31 | $-17.41M | (m) | $-17.25M | $162.14K | (m) | (m) | (m) | $-22.45M | (m) | (m) | (m) | 0.77× |
| 2025-09-30 | $-17.93M | (m) | $-17.73M | $204.39K | (m) | (m) | (m) | $-21.39M | (m) | (m) | (m) | 0.83× |
| 2025-06-30 | $-17.43M | (m) | $-17.37M | $63.59K | (m) | (m) | (m) | $-17.96M | (m) | (m) | (m) | 0.97× |
| 2025-03-31 | (m) | (m) | $-14.31M | (m) | (m) | (m) | (m) | $-16.38M | (m) | (m) | (m) | 0.87× |
| 2024-12-31 | $-18.66M | (m) | $-18.45M | $211.80K | (m) | (m) | (m) | $-15.55M | (m) | (m) | (m) | 1.19× |
| 2024-09-30 | $-17.13M | (m) | $-16.93M | $200.30K | (m) | (m) | (m) | $-16.35M | (m) | (m) | (m) | 1.04× |
| 2024-06-30 | $-17.68M | (m) | $-17.34M | $341.09K | (m) | (m) | (m) | $-19.10M | (m) | (m) | (m) | 0.91× |
| 2024-03-31 | $-20.47M | (m) | $-20.20M | $268.47K | (m) | (m) | (m) | $-22.50M | (m) | (m) | (m) | 0.90× |
| 2023-12-31 | $-15.26M | (m) | $-15.03M | $224.10K | (m) | (m) | (m) | $-23.53M | (m) | (m) | (m) | 0.64× |
| 2023-09-30 | $-16.86M | (m) | $-16.68M | $180.16K | (m) | (m) | (m) | $-21.21M | (m) | (m) | (m) | 0.79× |
| 2023-06-30 | $-15.97M | (m) | $-15.79M | $180.16K | (m) | (m) | (m) | $-19.25M | (m) | (m) | (m) | 0.82× |
| 2023-03-31 | $-15.77M | (m) | $-15.59M | $180.16K | (m) | (m) | (m) | $-16.68M | (m) | (m) | (m) | 0.94× |
| 2022-12-31 | $-16.04M | (m) | $-15.88M | $153.42K | (m) | (m) | (m) | $-17.68M | (m) | (m) | (m) | 0.90× |
| 2022-09-30 | $-17.02M | (m) | $-16.30M | $720.41K | (m) | (m) | (m) | $-15.72M | (m) | (m) | (m) | 1.04× |
| 2022-06-30 | $-16.22M | (m) | $-15.48M | $736.18K | (m) | (m) | (m) | $-26.99M | (m) | (m) | (m) | 0.57× |
| 2022-03-31 | $-13.38M | (m) | $-12.62M | $758.67K | (m) | (m) | (m) | $-24.38M | (m) | (m) | (m) | 0.52× |
| 2021-12-31 | $-11.25M | (m) | $-10.43M | $814.74K | (m) | (m) | (m) | $-20.71M | (m) | (m) | (m) | 0.50× |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-7.21M | (m) | $-6.81M | $402.10K | (m) | (m) | (m) | $-7.18M | (m) | (m) | (m) | 0.95× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |